Search
Oncotype DX for colon cancer
Indications:
- assessment of stage 1 or 2 colorectal carcinoma
Contraindications:
- not appropriate for carcinoma in situ
- not appropriate for metastatic cancer
Procedure:
- RT-PCR
- analyzes expression of 12 genes
- 3 genes are associated with activated stroma
- BGN, INHBA & FAP
- 3 genes are cell cycle associated
- MK167, MYBL2 & MYC
- 1 early-response or genotoxic stress pathway gene
- GADD45B
- 5 reference genes
- ATP5E, GPX1, PGK1, VDAC2, UBB
Specimen:
- tissue from colorectal biopsy or surgical specimens
Notes:
- introduced in 2010
Related
prostate cancer
General
Oncotype DX
References
- Gray RG, Quirke P, Handley K, et al.
Validation Study of a Quantitative Multigene Reverse
Transcriptase-Polymerase Chain Reaction Assay for Assessment of
Recurrence Risk in Patients With Stage II Colon Cancer
J Clin Oncol. 2011; 29(32):
PMID: 22067390
- Clark-Langone KM, Sangli C, Krishnakumar J, Watson D.
Translating tumor biology into personalized treatment planning:
analytical performance characteristics of the Oncotype DX
Colon Cancer Assay.
BMC Cancer. 2010 Dec 23;10:691
PMID: 21176237